Organic cation transporters are determinants of oxaliplatin cytotoxicity.
about
Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancerPharmacologic resistance in colorectal cancer: a reviewFOLFOX/FOLFIRI pharmacogenetics: the call for a personalized approach in colorectal cancer therapyRole of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyRole of solute carriers in response to anticancer drugscis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsMultidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane VesiclesEsters of Bendamustine Are by Far More Potent Cytotoxic Agents than the Parent Compound against Human Sarcoma and Carcinoma CellsA novel approach using C. elegans DNA damage-induced apoptosis to characterize the dynamics of uptake transporters for therapeutic drug discoveriesMembrane transporters as mediators of Cisplatin effects and side effects.Organic cation transporter 2 mediates cisplatin-induced oto- and nephrotoxicity and is a target for protective interventions.Role of the copper transporter, CTR1, in platinum-induced ototoxicity.Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2).Xenobiotic, bile acid, and cholesterol transporters: function and regulation.New frontiers in the treatment of colorectal cancer: Autophagy and the unfolded protein response as promising targetsDiscovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modelingComparison of human solute carriersProfiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2Cisplatin-induced renal injury is independently mediated by OCT2 and p53.Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 yearsUptake of pramipexole by human organic cation transporters.Genetic variants in multidrug and toxic compound extrusion-1, hMATE1, alter transport function.High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.Downregulation of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) in human hepatocellular carcinoma and their prognostic significance.Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.Nanocarriers for delivery of platinum anticancer drugs.Understanding and improving platinum anticancer drugs--phenanthriplatinEvaluation of the transporter-mediated herb-drug interaction potential of DA-9801, a standardized dioscorea extract for diabetic neuropathy, in human in vitro and rat in vivo.Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice.Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteinsOrganic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.Third row transition metals for the treatment of cancerSpectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cellsFunctional characterization of liver enhancers that regulate drug-associated transporters.Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cellsOrganic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue.Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin actionAssessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study
P2860
Q24201720-8B8D4DC4-9919-4159-BA6E-224837D00D9FQ26769850-3E8EE976-1300-4809-9B28-0D0F1E76CF10Q26851060-1F1190CD-EC21-4380-82DE-7D1F22B8F7CFQ27026858-3BEEB2D9-681E-4CCD-970F-D08A8ACAD8BFQ27027625-199E651D-DAE9-47CF-93F8-E6D0BB9B1EE1Q27650949-5AC06905-7B2B-467E-9DA3-2E1892193DEAQ28066801-C9F5056A-96BA-4A18-9956-624225F81A83Q28546068-815F8BC3-5EEB-42F5-B394-24A4400F8D39Q28552720-15E50E8F-C9F6-4C68-94AC-81EE6971927EQ28820987-B202C760-5131-4FB5-A84E-B56FD46C52DBQ30446860-66C4B7AC-891D-42A7-A5BA-2D0E64E76903Q30476563-E8FEADF4-2028-4C85-9556-FC77F01C4E41Q30477867-634AD18C-83B2-4865-929B-C137C707B3CBQ33480591-F88C006A-DED0-4C1F-816C-0649278F45F1Q33523365-CF1C16C9-F3FE-4708-BED7-025421524CC0Q33714593-56471BB0-0434-46EC-AC15-E4C11D213308Q33731804-F3B7F086-6968-4C69-94CC-EA6443BD0807Q33799288-78278502-49D7-41C9-AFC4-721E544B786FQ33836276-DEE485B3-3BB6-49F4-AA10-EB347BB36A4BQ33907033-2014B622-E317-49BA-AB88-D2BB57DBFC34Q33992572-6090670A-1344-4617-ACB6-B7D36B32DA66Q34008793-5444CDBE-4F4A-4A30-8655-29B5C7AA2F92Q34037009-F2DCBB03-7156-4ADE-9D73-AA1F72DCEA11Q34170589-F24EAA3F-D01E-400D-90D6-D1EEA14EA701Q34178509-D27D61E6-0436-4145-8AB7-7142114E34D2Q34206748-F29B124B-5CF2-420C-9398-CDEC877567F8Q34292544-1550785B-A13A-46E5-B4B1-0C5DCBCF3C4AQ34338695-49112015-A228-4AA9-A36E-08CDD3A7E0EDQ34396623-69E1013A-258C-4864-8F61-0725B3B96613Q34469619-07626600-5F67-48DC-B997-1BF117596206Q34579707-A7AA4D83-245E-4FC3-AC27-6B0DB7D474E5Q34714353-1394F646-E05B-4BB6-B8AE-14850136B8B1Q35026167-C2CDE1B1-A660-4471-91ED-9C2F6AAC1EE4Q35128394-F99C9B95-CE1F-4664-8F1C-8A3A23A2FC1BQ35206753-AFA3FBF1-3AB3-43F1-B7B4-DAFA64F93E85Q35583006-7D5E9585-D8E8-4518-8DD0-F317FA2C658EQ35647227-764D329B-1AD4-423D-B9A8-EEC33E8B7D58Q35671906-EA7401BC-7CC9-43A1-8A6D-72BD606D87F9Q35762110-2A05A744-6C30-4756-B417-7D1ABF0EF4DEQ35918413-493DBA3C-C468-4CFD-90DF-FC29B940CD79
P2860
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2006
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
@en
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
@nl
type
label
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
@en
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
@nl
prefLabel
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
@en
Organic cation transporters are determinants of oxaliplatin cytotoxicity.
@nl
P2093
P2860
P1433
P1476
Organic cation transporters are determinants of oxaliplatin cytotoxicity
@en
P2093
Anna Lapuk
James E Shima
Joe W Gray
Kathleen M Giacomini
Leah L Lagpacan
Shuzhong Zhang
Stephen J Lippard
Takafumi Komori
P2860
P304
P356
10.1158/0008-5472.CAN-06-0769
P407
P577
2006-09-01T00:00:00Z